Author:
Spielmann M,Tubiana-Hulin M,Namer M,Mansouri H,Bougnoux P h,Tubiana-Mathieu N,Lotz V,Eymard J C
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. A'Hern RP, Smith IE, Ebbs S (1993) Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67: 801–805
2. Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273: 542–547
3. Bonneterre J, Spielmann M, Guastalla J-P, Marty M, Viens P, Chollet P, Roché H, Fumoleau P, Mauriac L, Bourgeois H, Namer M, Bergerat JP, Misset J-L, Trandafir L, Mahjoubi M (1999) Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French Compassionate Use Programme Experience. Eur J Cancer 35: 1431–1439
4. Burris III HA (2000) Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab. Semin Oncol 27: 19–23
5. Campora E, Gardin G, Gasco M, Rosso R, Santi L (1999) Metastatic breast cancer patients failing first-line, anthracycline-containing chemotherapy: is further therapy of benefit? Anticancer Res 19: 3429–3432
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献